APO Research
Talk to an analyst

APO RESEARCH · REPORT

Cancer Immunotherapy Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Cancer Immunotherapy Drugs Market Outlook and Growth Opportunities 2026

2 January 2026209 pages

Choose your research edition.

Industry ResearchCancer Immunotherapy Drugs Industry Research Report 2026142 pages · $2,950 USDIndustry Growth & TrendsGlobal Cancer Immunotherapy Drugs Industry Growth and Trends Forecast to 2032129 pages · $3,450 USDMarket StructureGlobal Cancer Immunotherapy Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Cancer Immunotherapy Drugs Market Outlook and Growth Opportunities 2026209 pages · $4,250 USDMarket Analysis & ForecastGlobal Cancer Immunotherapy Drugs Market Analysis and Forecast 2026-2032209 pages · $4,950 USD

Market perspective

The global Cancer Immunotherapy Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Cancer Immunotherapy Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Cancer Immunotherapy Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Cancer Immunotherapy Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Cancer Immunotherapy Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Cancer Immunotherapy Drugs market include Takeda, Johnson & Johnson, Novartis, Merck KGaA, Roche, Eli Lilly, Pfizer, GSK and Amgen, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Cancer Immunotherapy Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Cancer Immunotherapy Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Cancer Immunotherapy Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Cancer Immunotherapy Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Cancer Immunotherapy Drugs Segment by Company

Takeda

Johnson & Johnson

Novartis

Merck KGaA

Roche

Eli Lilly

Pfizer

GSK

Amgen

AbbVie

AstraZeneca

Seagen

Regeneron

Ono Pharmaceutical

Merck & Co

Innovent

Hengrui Medicine

Gilead Sciences

Exelixis

Bristol-Myers Squibb

Cancer Immunotherapy Drugs Segment by Type

CAR-T Cell Therapy

Cytokine-Based Immunotherapy

Immune Checkpoint Inhibitors

Other

Cancer Immunotherapy Drugs Segment by Application

Blood-related Cancer

Breast Cancer

Prostate Cancer

Lung Cancer

Other

Cancer Immunotherapy Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Cancer Immunotherapy Drugs status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Cancer Immunotherapy Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Cancer Immunotherapy Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze Cancer Immunotherapy Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Cancer Immunotherapy Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Cancer Immunotherapy Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Cancer Immunotherapy Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Cancer Immunotherapy Drugs market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Cancer Immunotherapy Drugs industry.

Chapter 3: Detailed analysis of Cancer Immunotherapy Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Cancer Immunotherapy Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Cancer Immunotherapy Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Cancer Immunotherapy Drugs Industry Trends Table 2. Cancer Immunotherapy Drugs Industry Drivers Table 3. Cancer Immunotherapy Drugs Industry Opportunities and Challenges Table 4. Cancer Immunotherapy Drugs Industry Restraints Table 5. Global Cancer Immunotherapy Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Cancer Immunotherapy Drugs Revenue Share by Company (2021-2026) Table 7. Global Cancer Immunotherapy Drugs Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Cancer Immunotherapy Drugs Sales Volume Share by Company (2021-2026) Table 9. Global Cancer Immunotherapy Drugs Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Cancer Immunotherapy Drugs Company Ranking, (2024-2026) & (USD Million) Table 11. Global Cancer Immunotherapy Drugs Key Company Manufacturing Base & Headquarters Table 12. Global Cancer Immunotherapy Drugs Company, Product Type & Application Table 13. Global Cancer Immunotherapy Drugs Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Cancer Immunotherapy Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of CAR-T Cell Therapy Table 18. Significant Companies of Cytokine-Based Immunotherapy Table 19. Significant Companies of Immune Checkpoint Inhibitors Table 20. Significant Companies of Other Table 21. Global Cancer Immunotherapy Drugs Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 22. Global Cancer Immunotherapy Drugs Sales Volume by Type (2021-2026) & (K Units) Table 23. Global Cancer Immunotherapy Drugs Sales Volume by Type (2027-2032) & (K Units) Table 24. Global Cancer Immunotherapy Drugs Sales Volume Share by Type (2021-2026) Table 25. Global Cancer Immunotherapy Drugs Sales Volume Share by Type (2027-2032) Table 26. Global Cancer Immunotherapy Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Cancer Immunotherapy Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 28. Global Cancer Immunotherapy Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 29. Global Cancer Immunotherapy Drugs Sales Value Share by Type (2021-2026) Table 30. Global Cancer Immunotherapy Drugs Sales Value Share by Type (2027-2032) Table 31. Significant Companies of Blood-related Cancer Table 32. Significant Companies of Breast Cancer Table 33. Significant Companies of Prostate Cancer Table 34. Significant Companies of Lung Cancer Table 35. Significant Companies of Other Table 36. Global Cancer Immunotherapy Drugs Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 37. Global Cancer Immunotherapy Drugs Sales Volume by Application (2021-2026) & (K Units) Table 38. Global Cancer Immunotherapy Drugs Sales Volume by Application (2027-2032) & (K Units) Table 39. Global Cancer Immunotherapy Drugs Sales Volume Share by Application (2021-2026) Table 40. Global Cancer Immunotherapy Drugs Sales Volume Share by Application (2027-2032) Table 41. Global Cancer Immunotherapy Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 42. Global Cancer Immunotherapy Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 43. Global Cancer Immunotherapy Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 44. Global Cancer Immunotherapy Drugs Sales Value Share by Application (2021-2026) Table 45. Global Cancer Immunotherapy Drugs Sales Value Share by Application (2027-2032) Table 46. Global Cancer Immunotherapy Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 47. Global Cancer Immunotherapy Drugs Sales by Region (2021-2026) & (K Units) Table 48. Global Cancer Immunotherapy Drugs Sales Market Share by Region (2021-2026) Table 49. Global Cancer Immunotherapy Drugs Sales by Region (2027-2032) & (K Units) Table 50. Global Cancer Immunotherapy Drugs Sales Market Share by Region (2027-2032) Table 51. Global Cancer Immunotherapy Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 52. Global Cancer Immunotherapy Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 53. Global Cancer Immunotherapy Drugs Sales Value Share by Region (2021-2026) Table 54. Global Cancer Immunotherapy Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 55. Global Cancer Immunotherapy Drugs Sales Value Share by Region (2027-2032) Table 56. Global Cancer Immunotherapy Drugs Market Average Price (US$/Unit) by Region (2021-2026) Table 57. Global Cancer Immunotherapy Drugs Market Average Price (US$/Unit) by Region (2027-2032) Table 58. Global Cancer Immunotherapy Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 59. Global Cancer Immunotherapy Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 60. Global Cancer Immunotherapy Drugs Sales by Country (2021-2026) & (K Units) Table 61. Global Cancer Immunotherapy Drugs Sales Market Share by Country (2021-2026) Table 62. Global Cancer Immunotherapy Drugs Sales by Country (2027-2032) & (K Units) Table 63. Global Cancer Immunotherapy Drugs Sales Market Share by Country (2027-2032) Table 64. Global Cancer Immunotherapy Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 65. Global Cancer Immunotherapy Drugs Sales Value Market Share by Country (2021-2026) Table 66. Global Cancer Immunotherapy Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 67. Global Cancer Immunotherapy Drugs Sales Value Market Share by Country (2027-2032) Table 68. Takeda Company Information Table 69. Takeda Business Overview Table 70. Takeda Cancer Immunotherapy Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. Takeda Cancer Immunotherapy Drugs Product Portfolio Table 72. Takeda Recent Development Table 73. Johnson & Johnson Company Information Table 74. Johnson & Johnson Business Overview Table 75. Johnson & Johnson Cancer Immunotherapy Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Johnson & Johnson Cancer Immunotherapy Drugs Product Portfolio Table 77. Johnson & Johnson Recent Development Table 78. Novartis Company Information Table 79. Novartis Business Overview Table 80. Novartis Cancer Immunotherapy Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Novartis Cancer Immunotherapy Drugs Product Portfolio Table 82. Novartis Recent Development Table 83. Merck KGaA Company Information Table 84. Merck KGaA Business Overview Table 85. Merck KGaA Cancer Immunotherapy Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. Merck KGaA Cancer Immunotherapy Drugs Product Portfolio Table 87. Merck KGaA Recent Development Table 88. Roche Company Information Table 89. Roche Business Overview Table 90. Roche Cancer Immunotherapy Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Roche Cancer Immunotherapy Drugs Product Portfolio Table 92. Roche Recent Development Table 93. Eli Lilly Company Information Table 94. Eli Lilly Business Overview Table 95. Eli Lilly Cancer Immunotherapy Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Eli Lilly Cancer Immunotherapy Drugs Product Portfolio Table 97. Eli Lilly Recent Development Table 98. Pfizer Company Information Table 99. Pfizer Business Overview Table 100. Pfizer Cancer Immunotherapy Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. Pfizer Cancer Immunotherapy Drugs Product Portfolio Table 102. Pfizer Recent Development Table 103. GSK Company Information Table 104. GSK Business Overview Table 105. GSK Cancer Immunotherapy Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 106. GSK Cancer Immunotherapy Drugs Product Portfolio Table 107. GSK Recent Development Table 108. Amgen Company Information Table 109. Amgen Business Overview Table 110. Amgen Cancer Immunotherapy Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 111. Amgen Cancer Immunotherapy Drugs Product Portfolio Table 112. Amgen Recent Development Table 113. AbbVie Company Information Table 114. AbbVie Business Overview Table 115. AbbVie Cancer Immunotherapy Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 116. AbbVie Cancer Immunotherapy Drugs Product Portfolio Table 117. AbbVie Recent Development Table 118. AstraZeneca Company Information Table 119. AstraZeneca Business Overview Table 120. AstraZeneca Cancer Immunotherapy Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 121. AstraZeneca Cancer Immunotherapy Drugs Product Portfolio Table 122. AstraZeneca Recent Development Table 123. Seagen Company Information Table 124. Seagen Business Overview Table 125. Seagen Cancer Immunotherapy Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 126. Seagen Cancer Immunotherapy Drugs Product Portfolio Table 127. Seagen Recent Development Table 128. Regeneron Company Information Table 129. Regeneron Business Overview Table 130. Regeneron Cancer Immunotherapy Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 131. Regeneron Cancer Immunotherapy Drugs Product Portfolio Table 132. Regeneron Recent Development Table 133. Ono Pharmaceutical Company Information Table 134. Ono Pharmaceutical Business Overview Table 135. Ono Pharmaceutical Cancer Immunotherapy Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 136. Ono Pharmaceutical Cancer Immunotherapy Drugs Product Portfolio Table 137. Ono Pharmaceutical Recent Development Table 138. Merck & Co Company Information Table 139. Merck & Co Business Overview Table 140. Merck & Co Cancer Immunotherapy Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 141. Merck & Co Cancer Immunotherapy Drugs Product Portfolio Table 142. Merck & Co Recent Development Table 143. Innovent Company Information Table 144. Innovent Business Overview Table 145. Innovent Cancer Immunotherapy Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 146. Innovent Cancer Immunotherapy Drugs Product Portfolio Table 147. Innovent Recent Development Table 148. Hengrui Medicine Company Information Table 149. Hengrui Medicine Business Overview Table 150. Hengrui Medicine Cancer Immunotherapy Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 151. Hengrui Medicine Cancer Immunotherapy Drugs Product Portfolio Table 152. Hengrui Medicine Recent Development Table 153. Gilead Sciences Company Information Table 154. Gilead Sciences Business Overview Table 155. Gilead Sciences Cancer Immunotherapy Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 156. Gilead Sciences Cancer Immunotherapy Drugs Product Portfolio Table 157. Gilead Sciences Recent Development Table 158. Exelixis Company Information Table 159. Exelixis Business Overview Table 160. Exelixis Cancer Immunotherapy Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 161. Exelixis Cancer Immunotherapy Drugs Product Portfolio Table 162. Exelixis Recent Development Table 163. Bristol-Myers Squibb Company Information Table 164. Bristol-Myers Squibb Business Overview Table 165. Bristol-Myers Squibb Cancer Immunotherapy Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 166. Bristol-Myers Squibb Cancer Immunotherapy Drugs Product Portfolio Table 167. Bristol-Myers Squibb Recent Development Table 168. Key Raw Materials Table 169. Raw Materials Key Suppliers Table 170. Cancer Immunotherapy Drugs Distributors List Table 171. Cancer Immunotherapy Drugs Customers List Table 172. Research Programs/Design for This Report Table 173. Authors List of This Report Table 174. Secondary Sources Table 175. Primary Sources List of Figures Figure 1. Cancer Immunotherapy Drugs Product Image Figure 2. Global Cancer Immunotherapy Drugs Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Cancer Immunotherapy Drugs Sales Value (2021-2032) & (US$ Million) Figure 4. Global Cancer Immunotherapy Drugs Sales (2021-2032) & (K Units) Figure 5. Global Cancer Immunotherapy Drugs Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Cancer Immunotherapy Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. CAR-T Cell Therapy Image Figure 10. Cytokine-Based Immunotherapy Image Figure 11. Immune Checkpoint Inhibitors Image Figure 12. Other Image Figure 13. Global Cancer Immunotherapy Drugs Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global Cancer Immunotherapy Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 15. Global Cancer Immunotherapy Drugs Sales Volume Share by Type (2021-2032) Figure 16. Global Cancer Immunotherapy Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Cancer Immunotherapy Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Cancer Immunotherapy Drugs Sales Value Share by Type (2021-2032) Figure 19. Blood-related Cancer Image Figure 20. Breast Cancer Image Figure 21. Prostate Cancer Image Figure 22. Lung Cancer Image Figure 23. Other Image Figure 24. Global Cancer Immunotherapy Drugs Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 25. Global Cancer Immunotherapy Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 26. Global Cancer Immunotherapy Drugs Sales Volume Share by Application (2021-2032) Figure 27. Global Cancer Immunotherapy Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 28. Global Cancer Immunotherapy Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 29. Global Cancer Immunotherapy Drugs Sales Value Share by Application (2021-2032) Figure 30. Global Cancer Immunotherapy Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 31. Global Cancer Immunotherapy Drugs Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 32. Global Cancer Immunotherapy Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 33. Global Cancer Immunotherapy Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 34. North America Cancer Immunotherapy Drugs Sales Value (2021-2032) & (US$ Million) Figure 35. North America Cancer Immunotherapy Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Europe Cancer Immunotherapy Drugs Sales Value (2021-2032) & (US$ Million) Figure 37. Europe Cancer Immunotherapy Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Asia-Pacific Cancer Immunotherapy Drugs Sales Value (2021-2032) & (US$ Million) Figure 39. Asia-Pacific Cancer Immunotherapy Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 40. South America Cancer Immunotherapy Drugs Sales Value (2021-2032) & (US$ Million) Figure 41. South America Cancer Immunotherapy Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 42. Middle East & Africa Cancer Immunotherapy Drugs Sales Value (2021-2032) & (US$ Million) Figure 43. Middle East & Africa Cancer Immunotherapy Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 44. USA Cancer Immunotherapy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. USA Cancer Immunotherapy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. USA Cancer Immunotherapy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Canada Cancer Immunotherapy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Canada Cancer Immunotherapy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Canada Cancer Immunotherapy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Mexico Cancer Immunotherapy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Mexico Cancer Immunotherapy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Mexico Cancer Immunotherapy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Germany Cancer Immunotherapy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Germany Cancer Immunotherapy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Germany Cancer Immunotherapy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. France Cancer Immunotherapy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. France Cancer Immunotherapy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. France Cancer Immunotherapy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. U.K. Cancer Immunotherapy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. U.K. Cancer Immunotherapy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. U.K. Cancer Immunotherapy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Italy Cancer Immunotherapy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Italy Cancer Immunotherapy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Italy Cancer Immunotherapy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Spain Cancer Immunotherapy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Spain Cancer Immunotherapy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Spain Cancer Immunotherapy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Russia Cancer Immunotherapy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Russia Cancer Immunotherapy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Russia Cancer Immunotherapy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Netherlands Cancer Immunotherapy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Netherlands Cancer Immunotherapy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Netherlands Cancer Immunotherapy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. Nordic Countries Cancer Immunotherapy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. Nordic Countries Cancer Immunotherapy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. Nordic Countries Cancer Immunotherapy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. China Cancer Immunotherapy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. China Cancer Immunotherapy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. China Cancer Immunotherapy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Japan Cancer Immunotherapy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Japan Cancer Immunotherapy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Japan Cancer Immunotherapy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. South Korea Cancer Immunotherapy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. South Korea Cancer Immunotherapy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. South Korea Cancer Immunotherapy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. India Cancer Immunotherapy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. India Cancer Immunotherapy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. India Cancer Immunotherapy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Australia Cancer Immunotherapy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Australia Cancer Immunotherapy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Australia Cancer Immunotherapy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Southeast Asia Cancer Immunotherapy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Southeast Asia Cancer Immunotherapy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Southeast Asia Cancer Immunotherapy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Brazil Cancer Immunotherapy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Brazil Cancer Immunotherapy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Brazil Cancer Immunotherapy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Argentina Cancer Immunotherapy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Argentina Cancer Immunotherapy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Argentina Cancer Immunotherapy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Chile Cancer Immunotherapy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Chile Cancer Immunotherapy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Chile Cancer Immunotherapy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Colombia Cancer Immunotherapy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Colombia Cancer Immunotherapy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Colombia Cancer Immunotherapy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Peru Cancer Immunotherapy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Peru Cancer Immunotherapy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Peru Cancer Immunotherapy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Saudi Arabia Cancer Immunotherapy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Saudi Arabia Cancer Immunotherapy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Saudi Arabia Cancer Immunotherapy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Israel Cancer Immunotherapy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Israel Arabia Cancer Immunotherapy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Israel Arabia Cancer Immunotherapy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. UAE Cancer Immunotherapy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. UAE Cancer Immunotherapy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. UAE Cancer Immunotherapy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Turkey Cancer Immunotherapy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Turkey Cancer Immunotherapy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Turkey Cancer Immunotherapy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Iran Cancer Immunotherapy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Iran Cancer Immunotherapy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Iran Cancer Immunotherapy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Egypt Cancer Immunotherapy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 126. Egypt Cancer Immunotherapy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 127. Egypt Cancer Immunotherapy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 128. Cancer Immunotherapy Drugs Value Chain Figure 129. Manufacturing Cost Structure Figure 130. Cancer Immunotherapy Drugs Sales Mode & Process Figure 131. Direct Comparison with Distribution Share Figure 132. Distributors Profiles Figure 133. Years Considered Figure 134. Research Process Figure 135. Key Executives Interviewed

Scope & coverage.

Types
  • CAR-T Cell Therapy
  • Cytokine-Based Immunotherapy
  • Immune Checkpoint Inhibitors
  • Other
Applications
  • Blood-related Cancer
  • Breast Cancer
  • Prostate Cancer
  • Lung Cancer
  • Other
Companies covered
  • Takeda
  • Johnson & Johnson
  • Novartis
  • Merck KGaA
  • Roche
  • Eli Lilly
  • Pfizer
  • GSK
  • Amgen
  • AbbVie
  • AstraZeneca
  • Seagen
  • Regeneron
  • Ono Pharmaceutical
  • Merck & Co
  • Innovent
  • Hengrui Medicine
  • Gilead Sciences
  • Exelixis
  • Bristol-Myers Squibb

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Cancer Immunotherapy Drugs Sales Value (2021-2032)
  4. 1.2.2 Global Cancer Immunotherapy Drugs Sales Volume (2021-2032)
  5. 1.2.3 Global Cancer Immunotherapy Drugs Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Cancer Immunotherapy Drugs Market Dynamics
  1. 2.1 Cancer Immunotherapy Drugs Industry Trends
  2. 2.2 Cancer Immunotherapy Drugs Industry Drivers
  3. 2.3 Cancer Immunotherapy Drugs Industry Opportunities and Challenges
  4. 2.4 Cancer Immunotherapy Drugs Industry Restraints
3 Cancer Immunotherapy Drugs Market by Company
  1. 3.1 Global Cancer Immunotherapy Drugs Company Revenue Ranking in 2025
  2. 3.2 Global Cancer Immunotherapy Drugs Revenue by Company (2021-2026)
  3. 3.3 Global Cancer Immunotherapy Drugs Sales Volume by Company (2021-2026)
  4. 3.4 Global Cancer Immunotherapy Drugs Average Price by Company (2021-2026)
  5. 3.5 Global Cancer Immunotherapy Drugs Company Ranking (2024-2026)
  6. 3.6 Global Cancer Immunotherapy Drugs Company Manufacturing Base and Headquarters
  7. 3.7 Global Cancer Immunotherapy Drugs Company Product Type and Application
  8. 3.8 Global Cancer Immunotherapy Drugs Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Cancer Immunotherapy Drugs Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Cancer Immunotherapy Drugs Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Cancer Immunotherapy Drugs Market by Type
  1. 4.1 Cancer Immunotherapy Drugs Type Introduction
  2. 4.1.1 CAR-T Cell Therapy
  3. 4.1.2 Cytokine-Based Immunotherapy
  4. 4.1.3 Immune Checkpoint Inhibitors
  5. 4.1.4 Other
  6. 4.2 Global Cancer Immunotherapy Drugs Sales Volume by Type
  7. 4.2.1 Global Cancer Immunotherapy Drugs Sales Volume by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Cancer Immunotherapy Drugs Sales Volume by Type (2021-2032)
  9. 4.2.3 Global Cancer Immunotherapy Drugs Sales Volume Share by Type (2021-2032)
  10. 4.3 Global Cancer Immunotherapy Drugs Sales Value by Type
  11. 4.3.1 Global Cancer Immunotherapy Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Cancer Immunotherapy Drugs Sales Value by Type (2021-2032)
  13. 4.3.3 Global Cancer Immunotherapy Drugs Sales Value Share by Type (2021-2032)
5 Cancer Immunotherapy Drugs Market by Application
  1. 5.1 Cancer Immunotherapy Drugs Application Introduction
  2. 5.1.1 Blood-related Cancer
  3. 5.1.2 Breast Cancer
  4. 5.1.3 Prostate Cancer
  5. 5.1.4 Lung Cancer
  6. 5.1.5 Other
  7. 5.2 Global Cancer Immunotherapy Drugs Sales Volume by Application
  8. 5.2.1 Global Cancer Immunotherapy Drugs Sales Volume by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global Cancer Immunotherapy Drugs Sales Volume by Application (2021-2032)
  10. 5.2.3 Global Cancer Immunotherapy Drugs Sales Volume Share by Application (2021-2032)
  11. 5.3 Global Cancer Immunotherapy Drugs Sales Value by Application
  12. 5.3.1 Global Cancer Immunotherapy Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  13. 5.3.2 Global Cancer Immunotherapy Drugs Sales Value by Application (2021-2032)
  14. 5.3.3 Global Cancer Immunotherapy Drugs Sales Value Share by Application (2021-2032)
6 Cancer Immunotherapy Drugs Regional Sales and Value Analysis
  1. 6.1 Global Cancer Immunotherapy Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Cancer Immunotherapy Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Cancer Immunotherapy Drugs Sales by Region: 2021-2026
  4. 6.2.2 Global Cancer Immunotherapy Drugs Sales by Region (2027-2032)
  5. 6.3 Global Cancer Immunotherapy Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Cancer Immunotherapy Drugs Sales Value by Region (2021-2032)
  7. 6.4.1 Global Cancer Immunotherapy Drugs Sales Value by Region: 2021-2026
  8. 6.4.2 Global Cancer Immunotherapy Drugs Sales Value by Region (2027-2032)
  9. 6.5 Global Cancer Immunotherapy Drugs Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Cancer Immunotherapy Drugs Sales Value (2021-2032)
  12. 6.6.2 North America Cancer Immunotherapy Drugs Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Cancer Immunotherapy Drugs Sales Value (2021-2032)
  15. 6.7.2 Europe Cancer Immunotherapy Drugs Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Cancer Immunotherapy Drugs Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Cancer Immunotherapy Drugs Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Cancer Immunotherapy Drugs Sales Value (2021-2032)
  21. 6.9.2 South America Cancer Immunotherapy Drugs Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Cancer Immunotherapy Drugs Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Cancer Immunotherapy Drugs Sales Value Share by Country, 2025 VS 2032
7 Cancer Immunotherapy Drugs Country-level Sales and Value Analysis
  1. 7.1 Global Cancer Immunotherapy Drugs Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Cancer Immunotherapy Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Cancer Immunotherapy Drugs Sales by Country (2021-2032)
  4. 7.3.1 Global Cancer Immunotherapy Drugs Sales by Country (2021-2026)
  5. 7.3.2 Global Cancer Immunotherapy Drugs Sales by Country (2027-2032)
  6. 7.4 Global Cancer Immunotherapy Drugs Sales Value by Country (2021-2032)
  7. 7.4.1 Global Cancer Immunotherapy Drugs Sales Value by Country (2021-2026)
  8. 7.4.2 Global Cancer Immunotherapy Drugs Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Cancer Immunotherapy Drugs Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Cancer Immunotherapy Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Cancer Immunotherapy Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Cancer Immunotherapy Drugs Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Cancer Immunotherapy Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Cancer Immunotherapy Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Cancer Immunotherapy Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Cancer Immunotherapy Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Cancer Immunotherapy Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Cancer Immunotherapy Drugs Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Cancer Immunotherapy Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Cancer Immunotherapy Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Cancer Immunotherapy Drugs Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Cancer Immunotherapy Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Cancer Immunotherapy Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Cancer Immunotherapy Drugs Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Cancer Immunotherapy Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Cancer Immunotherapy Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Cancer Immunotherapy Drugs Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Cancer Immunotherapy Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Cancer Immunotherapy Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Cancer Immunotherapy Drugs Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Cancer Immunotherapy Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Cancer Immunotherapy Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Cancer Immunotherapy Drugs Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Cancer Immunotherapy Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Cancer Immunotherapy Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Cancer Immunotherapy Drugs Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Cancer Immunotherapy Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Cancer Immunotherapy Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Cancer Immunotherapy Drugs Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Cancer Immunotherapy Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Cancer Immunotherapy Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Cancer Immunotherapy Drugs Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Cancer Immunotherapy Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Cancer Immunotherapy Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Cancer Immunotherapy Drugs Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Cancer Immunotherapy Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Cancer Immunotherapy Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Cancer Immunotherapy Drugs Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Cancer Immunotherapy Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Cancer Immunotherapy Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Cancer Immunotherapy Drugs Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Cancer Immunotherapy Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Cancer Immunotherapy Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Cancer Immunotherapy Drugs Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Cancer Immunotherapy Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Cancer Immunotherapy Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Cancer Immunotherapy Drugs Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Cancer Immunotherapy Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Cancer Immunotherapy Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Cancer Immunotherapy Drugs Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Cancer Immunotherapy Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Cancer Immunotherapy Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Cancer Immunotherapy Drugs Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Cancer Immunotherapy Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Cancer Immunotherapy Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Cancer Immunotherapy Drugs Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Cancer Immunotherapy Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Cancer Immunotherapy Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Cancer Immunotherapy Drugs Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Cancer Immunotherapy Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Cancer Immunotherapy Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Cancer Immunotherapy Drugs Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Cancer Immunotherapy Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Cancer Immunotherapy Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Cancer Immunotherapy Drugs Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Cancer Immunotherapy Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Cancer Immunotherapy Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Cancer Immunotherapy Drugs Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Cancer Immunotherapy Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Cancer Immunotherapy Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Cancer Immunotherapy Drugs Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Cancer Immunotherapy Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Cancer Immunotherapy Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Cancer Immunotherapy Drugs Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Cancer Immunotherapy Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Cancer Immunotherapy Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Cancer Immunotherapy Drugs Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Cancer Immunotherapy Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Cancer Immunotherapy Drugs Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Cancer Immunotherapy Drugs Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Cancer Immunotherapy Drugs Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Cancer Immunotherapy Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Takeda
  2. 8.1.1 Takeda Company Information
  3. 8.1.2 Takeda Business Overview
  4. 8.1.3 Takeda Cancer Immunotherapy Drugs Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Takeda Cancer Immunotherapy Drugs Product Portfolio
  6. 8.1.5 Takeda Recent Developments
  7. 8.2 Johnson & Johnson
  8. 8.2.1 Johnson & Johnson Company Information
  9. 8.2.2 Johnson & Johnson Business Overview
  10. 8.2.3 Johnson & Johnson Cancer Immunotherapy Drugs Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Johnson & Johnson Cancer Immunotherapy Drugs Product Portfolio
  12. 8.2.5 Johnson & Johnson Recent Developments
  13. 8.3 Novartis
  14. 8.3.1 Novartis Company Information
  15. 8.3.2 Novartis Business Overview
  16. 8.3.3 Novartis Cancer Immunotherapy Drugs Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Novartis Cancer Immunotherapy Drugs Product Portfolio
  18. 8.3.5 Novartis Recent Developments
  19. 8.4 Merck KGaA
  20. 8.4.1 Merck KGaA Company Information
  21. 8.4.2 Merck KGaA Business Overview
  22. 8.4.3 Merck KGaA Cancer Immunotherapy Drugs Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Merck KGaA Cancer Immunotherapy Drugs Product Portfolio
  24. 8.4.5 Merck KGaA Recent Developments
  25. 8.5 Roche
  26. 8.5.1 Roche Company Information
  27. 8.5.2 Roche Business Overview
  28. 8.5.3 Roche Cancer Immunotherapy Drugs Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Roche Cancer Immunotherapy Drugs Product Portfolio
  30. 8.5.5 Roche Recent Developments
  31. 8.6 Eli Lilly
  32. 8.6.1 Eli Lilly Company Information
  33. 8.6.2 Eli Lilly Business Overview
  34. 8.6.3 Eli Lilly Cancer Immunotherapy Drugs Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Eli Lilly Cancer Immunotherapy Drugs Product Portfolio
  36. 8.6.5 Eli Lilly Recent Developments
  37. 8.7 Pfizer
  38. 8.7.1 Pfizer Company Information
  39. 8.7.2 Pfizer Business Overview
  40. 8.7.3 Pfizer Cancer Immunotherapy Drugs Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Pfizer Cancer Immunotherapy Drugs Product Portfolio
  42. 8.7.5 Pfizer Recent Developments
  43. 8.8 GSK
  44. 8.8.1 GSK Company Information
  45. 8.8.2 GSK Business Overview
  46. 8.8.3 GSK Cancer Immunotherapy Drugs Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 GSK Cancer Immunotherapy Drugs Product Portfolio
  48. 8.8.5 GSK Recent Developments
  49. 8.9 Amgen
  50. 8.9.1 Amgen Company Information
  51. 8.9.2 Amgen Business Overview
  52. 8.9.3 Amgen Cancer Immunotherapy Drugs Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Amgen Cancer Immunotherapy Drugs Product Portfolio
  54. 8.9.5 Amgen Recent Developments
  55. 8.10 AbbVie
  56. 8.10.1 AbbVie Company Information
  57. 8.10.2 AbbVie Business Overview
  58. 8.10.3 AbbVie Cancer Immunotherapy Drugs Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 AbbVie Cancer Immunotherapy Drugs Product Portfolio
  60. 8.10.5 AbbVie Recent Developments
  61. 8.11 AstraZeneca
  62. 8.11.1 AstraZeneca Company Information
  63. 8.11.2 AstraZeneca Business Overview
  64. 8.11.3 AstraZeneca Cancer Immunotherapy Drugs Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 AstraZeneca Cancer Immunotherapy Drugs Product Portfolio
  66. 8.11.5 AstraZeneca Recent Developments
  67. 8.12 Seagen
  68. 8.12.1 Seagen Company Information
  69. 8.12.2 Seagen Business Overview
  70. 8.12.3 Seagen Cancer Immunotherapy Drugs Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Seagen Cancer Immunotherapy Drugs Product Portfolio
  72. 8.12.5 Seagen Recent Developments
  73. 8.13 Regeneron
  74. 8.13.1 Regeneron Company Information
  75. 8.13.2 Regeneron Business Overview
  76. 8.13.3 Regeneron Cancer Immunotherapy Drugs Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Regeneron Cancer Immunotherapy Drugs Product Portfolio
  78. 8.13.5 Regeneron Recent Developments
  79. 8.14 Ono Pharmaceutical
  80. 8.14.1 Ono Pharmaceutical Company Information
  81. 8.14.2 Ono Pharmaceutical Business Overview
  82. 8.14.3 Ono Pharmaceutical Cancer Immunotherapy Drugs Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Ono Pharmaceutical Cancer Immunotherapy Drugs Product Portfolio
  84. 8.14.5 Ono Pharmaceutical Recent Developments
  85. 8.15 Merck & Co
  86. 8.15.1 Merck & Co Company Information
  87. 8.15.2 Merck & Co Business Overview
  88. 8.15.3 Merck & Co Cancer Immunotherapy Drugs Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Merck & Co Cancer Immunotherapy Drugs Product Portfolio
  90. 8.15.5 Merck & Co Recent Developments
  91. 8.16 Innovent
  92. 8.16.1 Innovent Company Information
  93. 8.16.2 Innovent Business Overview
  94. 8.16.3 Innovent Cancer Immunotherapy Drugs Sales, Value and Gross Margin (2021-2026)
  95. 8.16.4 Innovent Cancer Immunotherapy Drugs Product Portfolio
  96. 8.16.5 Innovent Recent Developments
  97. 8.17 Hengrui Medicine
  98. 8.17.1 Hengrui Medicine Company Information
  99. 8.17.2 Hengrui Medicine Business Overview
  100. 8.17.3 Hengrui Medicine Cancer Immunotherapy Drugs Sales, Value and Gross Margin (2021-2026)
  101. 8.17.4 Hengrui Medicine Cancer Immunotherapy Drugs Product Portfolio
  102. 8.17.5 Hengrui Medicine Recent Developments
  103. 8.18 Gilead Sciences
  104. 8.18.1 Gilead Sciences Company Information
  105. 8.18.2 Gilead Sciences Business Overview
  106. 8.18.3 Gilead Sciences Cancer Immunotherapy Drugs Sales, Value and Gross Margin (2021-2026)
  107. 8.18.4 Gilead Sciences Cancer Immunotherapy Drugs Product Portfolio
  108. 8.18.5 Gilead Sciences Recent Developments
  109. 8.19 Exelixis
  110. 8.19.1 Exelixis Company Information
  111. 8.19.2 Exelixis Business Overview
  112. 8.19.3 Exelixis Cancer Immunotherapy Drugs Sales, Value and Gross Margin (2021-2026)
  113. 8.19.4 Exelixis Cancer Immunotherapy Drugs Product Portfolio
  114. 8.19.5 Exelixis Recent Developments
  115. 8.20 Bristol-Myers Squibb
  116. 8.20.1 Bristol-Myers Squibb Company Information
  117. 8.20.2 Bristol-Myers Squibb Business Overview
  118. 8.20.3 Bristol-Myers Squibb Cancer Immunotherapy Drugs Sales, Value and Gross Margin (2021-2026)
  119. 8.20.4 Bristol-Myers Squibb Cancer Immunotherapy Drugs Product Portfolio
  120. 8.20.5 Bristol-Myers Squibb Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Cancer Immunotherapy Drugs Value Chain Analysis
  2. 9.1.1 Cancer Immunotherapy Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Cancer Immunotherapy Drugs Sales Mode & Process
  6. 9.2 Cancer Immunotherapy Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Cancer Immunotherapy Drugs Distributors
  9. 9.2.3 Cancer Immunotherapy Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst